Impact of Netrin-1 in the Pathophysiology of Placenta Accreta Spectrum
Overview
The main goal of this study the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum. To delineate the role of netrin-1, neogenin – zeb1 signaling pathway in mechanism of morbidly adherent placenta.
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: November 1, 2021
Detailed Description
The main goal of this study is: – To shed light on the possible involvement of netrin-1 into the pathophysiology of placenta accrete spectrum. – To study the role of netrin-1 in Epithelial to mesenchymal transition as a possible pathophysiological mechanism of placenta accrete spectrum. – To delineate the role of netrin-1, neogenin – zeb1 signaling pathway in the progression of invasion of placenta accrete spectrum.
Arms, Groups and Cohorts
- group A
- group A : placental tissue of 30 patients with placenta accreta
- group B
- group B : placental tissue of 30 normal pregnancy as a control group
Clinical Trial Outcome Measures
Primary Measures
- impact of netrin-1 in the pathophysiology of placenta accreta spectrum
- Time Frame: baseline
- Estimation of local placental netrin-1 protein expression by immunohistochemistry , Estimation of local placental expression of neognin by immunohistochemistry. Estimation of local placental expression of Zeb-1 by immunohistochemistry
Participating in This Clinical Trial
Inclusion Criteria
- ages between 20 to 40 years will be included. – Gestational age: between 34 to 38 weeks. – History of previous cesarean sections. – Ultrasonographic findings suggestive PAS according to Jauniaux et al. (2018) : – Loss of the retro-placental clear zone. – Thinning of myometrium. – Abnormal placental lacunae. – Bladder wall interruption. – Placental bulge. – Exophytic placental mass. – Doppler findings suggestive PAS according to Jauniaux et al. (2018): – Subplacental hypervascularity. – Uterovesical hypervascularity/bridging vessels. – Vascular lacunae with turbulent flow/feeder vessels. Exclusion Criteria:
Fundal and middle anterior or posterior placenta. • Pregnancy associated with morbid conditions as: hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, and endocrinal disease.
Gender Eligibility: Female
Minimum Age: 20 Years
Maximum Age: 40 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Assiut University
- Provider of Information About this Clinical Study
- Principal Investigator: Hanaa Mohammed Mohammed Sayed, assistant lecturer – Assiut University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.